These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 27471864)

  • 41. Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.
    Mele G; Spina A; Guaragna G; Giannotta A; Melpignano A; Quarta G
    Leuk Lymphoma; 2014 May; 55(5):1191-3. PubMed ID: 23829305
    [No Abstract]   [Full Text] [Related]  

  • 42. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
    Usmani SZ; Cavenagh JD; Belch AR; Hulin C; Basu S; White D; Nooka A; Ervin-Haynes A; Yiu W; Nagarwala Y; Berger A; Pelligra CG; Guo S; Binder G; Gibson CJ; Facon T
    J Med Econ; 2016; 19(3):243-58. PubMed ID: 26517601
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.
    Wang M; Dimopoulos MA; Chen C; Cibeira MT; Attal M; Spencer A; Rajkumar SV; Yu Z; Olesnyckyj M; Zeldis JB; Knight RD; Weber DM
    Blood; 2008 Dec; 112(12):4445-51. PubMed ID: 18799726
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.
    Baertsch MA; Schlenzka J; Mai EK; Merz M; Hillengaß J; Raab MS; Hose D; Wuchter P; Ho AD; Jauch A; Hielscher T; Kunz C; Luntz S; Klein S; Schmidt-Wolf IG; Goerner M; Schmidt-Hieber M; Reimer P; Graeven U; Fenk R; Salwender H; Scheid C; Nogai A; Haenel M; Lindemann HW; Martin H; Noppeney R; Weisel K; Goldschmidt H
    BMC Cancer; 2016 Apr; 16():290. PubMed ID: 27114074
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
    Voorhees PM; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Costa LJ; Anderson LD; Nathwani N; Shah N; Efebera YA; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Orlowski RZ; Shain KH; Cowan AJ; Murphy S; Lutska Y; Pei H; Ukropec J; Vermeulen J; de Boer C; Hoehn D; Lin TS; Richardson PG
    Blood; 2020 Aug; 136(8):936-945. PubMed ID: 32325490
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of efficacy, safety, patients' quality of life, and doctors' occupational stress between lenalidomide-based and bortezomib-based induction in patients with newly diagnosed multiple myeloma.
    Xu L; Liu J; Huang B; Kuang L; Gu J; Chen M; Zou W; Li J
    Cancer Med; 2021 Mar; 10(5):1656-1667. PubMed ID: 33527753
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple.
    Schütz NP; Ochoa P; Duarte P; Remaggi G; Yantorno S; Corzo A; Zabaljauregui S; Shanley C; Lopresti S; Orlando S; Verri V; Quiroga L; García CA; Fernández V; Fantl D
    Hematol Oncol; 2020 Aug; 38(3):363-371. PubMed ID: 32196120
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Autologous HSCT with novel agent-based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma.
    Mori Y; Takizawa J; Katsuoka Y; Takezako N; Nagafuji K; Handa H; Kuroda J; Sunami K; Kamimura T; Ogawa R; Kikushige Y; Harada M; Akashi K; Miyamoto T;
    Cancer Sci; 2024 Jun; 115(6):2002-2011. PubMed ID: 38498976
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study.
    Moreau P; Joshua D; Chng WJ; Palumbo A; Goldschmidt H; Hájek R; Facon T; Ludwig H; Pour L; Niesvizky R; Oriol A; Rosiñol L; Suvorov A; Gaidano G; Pika T; Weisel K; Goranova-Marinova V; Gillenwater HH; Mohamed N; Aggarwal S; Feng S; Dimopoulos MA
    Leukemia; 2017 Jan; 31(1):115-122. PubMed ID: 27491641
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.
    Orlowski RZ; Moreau P; Niesvizky R; Ludwig H; Oriol A; Chng WJ; Goldschmidt H; Yang Z; Kimball AS; Dimopoulos M
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):522-530.e1. PubMed ID: 31160237
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
    Richardson PG; Xie W; Jagannath S; Jakubowiak A; Lonial S; Raje NS; Alsina M; Ghobrial IM; Schlossman RL; Munshi NC; Mazumder A; Vesole DH; Kaufman JL; Colson K; McKenney M; Lunde LE; Feather J; Maglio ME; Warren D; Francis D; Hideshima T; Knight R; Esseltine DL; Mitsiades CS; Weller E; Anderson KC
    Blood; 2014 Mar; 123(10):1461-9. PubMed ID: 24429336
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
    Totani H; Ri M; Kato C; Nakashima T; Suzuki N; Hagiwara S; Kanamori T; Murakami S; Masuda A; Kinoshita S; Yoshida T; Narita T; Ito A; Kusumoto S; Ishida T; Komatsu H; Iida S
    Int J Hematol; 2016 Mar; 103(3):316-21. PubMed ID: 26715148
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.
    Niesvizky R; Flinn IW; Rifkin R; Gabrail N; Charu V; Clowney B; Essell J; Gaffar Y; Warr T; Neuwirth R; Zhu Y; Elliott J; Esseltine DL; Niculescu L; Reeves J
    J Clin Oncol; 2015 Nov; 33(33):3921-9. PubMed ID: 26056177
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
    Jakubowiak AJ; Griffith KA; Reece DE; Hofmeister CC; Lonial S; Zimmerman TM; Campagnaro EL; Schlossman RL; Laubach JP; Raje NS; Anderson T; Mietzel MA; Harvey CK; Wear SM; Barrickman JC; Tendler CL; Esseltine DL; Kelley SL; Kaminski MS; Anderson KC; Richardson PG
    Blood; 2011 Jul; 118(3):535-43. PubMed ID: 21596852
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Containing Induction Therapy-A Single Institution Experience.
    Tanimura A; Hirai R; Nakamura M; Takeshita M; Togano T; Sekine R; Hagiwara S; Miwa A
    Gan To Kagaku Ryoho; 2020 May; 47(5):789-796. PubMed ID: 32408321
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
    Kumar S; Flinn I; Richardson PG; Hari P; Callander N; Noga SJ; Stewart AK; Turturro F; Rifkin R; Wolf J; Estevam J; Mulligan G; Shi H; Webb IJ; Rajkumar SV
    Blood; 2012 May; 119(19):4375-82. PubMed ID: 22422823
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
    Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M
    J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Consensus statement on the treatment of transplant-eligible patients with newly diagnosed multiple myeloma in New Zealand.
    Chien N; Romeril K; Baker B; Goodman H; Chan H
    N Z Med J; 2020 Dec; 133(1527):104-110. PubMed ID: 33332332
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
    Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
    Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
    Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC
    Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.